Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
Champions Oncology (NASDAQ:CSBR) has secured a radioactive materials license, enabling in-house preclinical studies with various radionuclides. This development enhances the company's capabilities in developing and evaluating targeted radiotherapeutics.
The license allows Champions to combine radionuclide-based therapeutic testing with their existing patient derived xenograft (PDX) models platform under one roof. The integrated program will support drug developers in various modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.
CEO Ronnie Morris emphasized that this license represents a significant milestone in supporting biopharmaceutical partners developing next-generation radiotherapeutics, positioning the company to advance radiopharmaceutical development with enhanced translational precision.
Champions Oncology (NASDAQ:CSBR) ha ottenuto una licenza per materiali radioattivi, che consente di condurre internamente studi preclinici con diversi radionuclidi. Questo sviluppo potenzia le capacità dell'azienda nello sviluppo e nella valutazione di radioterapici mirati.
La licenza permette a Champions di combinare i test terapeutici basati su radionuclidi con la loro piattaforma esistente di modelli xenotrapianti derivati da pazienti (PDX) sotto un unico tetto. Il programma integrato supporterà gli sviluppatori di farmaci in varie modalità, inclusi coniugati anticorpo-radionuclide e radionuclidi recettoriali peptidici.
Il CEO Ronnie Morris ha sottolineato che questa licenza rappresenta un traguardo importante nel supportare i partner biofarmaceutici che sviluppano radioterapici di nuova generazione, posizionando l'azienda per avanzare nello sviluppo di radiofarmaci con maggiore precisione traslazionale.
Champions Oncology (NASDAQ:CSBR) ha obtenido una licencia para materiales radiactivos, lo que permite realizar estudios preclínicos internos con varios radionúclidos. Este avance mejora las capacidades de la compañía en el desarrollo y evaluación de terapias radioterapéuticas dirigidas.
La licencia permite a Champions combinar las pruebas terapéuticas basadas en radionúclidos con su plataforma existente de modelos de xenoinjertos derivados de pacientes (PDX) bajo un mismo techo. El programa integrado apoyará a los desarrolladores de fármacos en diversas modalidades, incluyendo conjugados anticuerpo-radionúclido y radionúclidos de receptores peptídicos.
El CEO Ronnie Morris destacó que esta licencia representa un hito importante para apoyar a los socios biofarmacéuticos que desarrollan terapias radioterapéuticas de próxima generación, posicionando a la empresa para avanzar en el desarrollo de radiofármacos con mayor precisión traslacional.
Champions Oncology (NASDAQ:CSBR)는 방사성 물질 사용 허가를 획득하여 다양한 방사성핵종을 활용한 사내 전임상 연구가 가능해졌습니다. 이번 허가는 표적 방사선 치료제 개발 및 평가 역량을 강화합니다.
이 허가를 통해 Champions는 방사성핵종 기반 치료 테스트를 기존의 환자 유래 이식편(PDX) 모델 플랫폼과 통합하여 한 곳에서 진행할 수 있게 되었습니다. 통합 프로그램은 항체-방사성핵종 결합체 및 펩타이드 수용체 방사성핵종을 포함한 다양한 치료제 개발을 지원합니다.
CEO Ronnie Morris는 이번 허가가 차세대 방사선 치료제를 개발하는 바이오제약 파트너들을 지원하는 중요한 이정표라며, 회사가 향상된 변환 정밀도로 방사성의약품 개발을 진전시킬 수 있는 위치에 있다고 강조했습니다.
Champions Oncology (NASDAQ:CSBR) a obtenu une licence pour les matériaux radioactifs, permettant la réalisation d'études précliniques en interne avec divers radionucléides. Cette avancée renforce les capacités de l'entreprise dans le développement et l'évaluation de radiothérapeutiques ciblées.
La licence permet à Champions de combiner les tests thérapeutiques basés sur les radionucléides avec leur plateforme existante de modèles de xénogreffes dérivées de patients (PDX) sous un même toit. Le programme intégré soutiendra les développeurs de médicaments dans diverses modalités, y compris les conjugués anticorps-radionucléides et radionucléides à récepteurs peptidiques.
Le PDG Ronnie Morris a souligné que cette licence représente une étape importante pour soutenir les partenaires biopharmaceutiques développant des radiothérapeutiques de nouvelle génération, positionnant l'entreprise pour faire progresser le développement de radiopharmaceutiques avec une précision translationnelle accrue.
Champions Oncology (NASDAQ:CSBR) hat eine Lizenz für radioaktive Materialien erhalten, die es ermöglicht, interne präklinische Studien mit verschiedenen Radionukliden durchzuführen. Diese Entwicklung erweitert die Fähigkeiten des Unternehmens bei der Entwicklung und Bewertung zielgerichteter Radiotherapeutika.
Die Lizenz erlaubt es Champions, radionuklidbasierte therapeutische Tests mit ihrer bestehenden Plattform für patientenabgeleitete Xenotransplantat-Modelle (PDX) unter einem Dach zu vereinen. Das integrierte Programm wird Arzneimittelentwickler in verschiedenen Modalitäten unterstützen, einschließlich Antikörper-Radionuklid-Konjugaten und peptidrezeptorbasierten Radionukliden.
CEO Ronnie Morris betonte, dass diese Lizenz einen bedeutenden Meilenstein darstellt, um biopharmazeutische Partner bei der Entwicklung der nächsten Generation von Radiotherapeutika zu unterstützen und das Unternehmen in die Lage versetzt, die Entwicklung von Radiopharmazeutika mit verbesserter translationaler Präzision voranzutreiben.
- Obtained radioactive materials license for in-house preclinical studies
- Integration of radionuclide testing with existing PDX platform creates unique market position
- Expanded capabilities in radiotherapeutics development and assessment
- None.
Insights
Champions Oncology's new radioactive materials license enables integrated radiotherapeutic testing with PDX models, strengthening their preclinical oncology research platform.
Champions Oncology has secured a critical regulatory milestone with its new license to use radioactive materials in preclinical studies. This approval enables in-house work with various clinically relevant radionuclides, significantly expanding their technical capabilities in radiotherapeutic assessment.
The most notable aspect is how this integrates with their patient-derived xenograft (PDX) models. PDX models maintain the biological characteristics of original human tumors, providing highly translational research platforms. By bringing radiotherapeutic testing capabilities under the same roof as their established PDX platform, Champions creates a more comprehensive and streamlined research workflow.
This integration allows Champions to support pharmaceutical clients developing several radiopharmaceutical modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides - both emerging areas in targeted cancer treatment. The ability to conduct these specialized studies in-house eliminates coordination challenges between multiple service providers, potentially accelerating development timelines.
This capability expansion positions Champions to better serve the growing radiopharmaceutical sector, which is gaining significant traction in oncology due to its precision in delivering radiation directly to cancer cells while minimizing damage to healthy tissue.
Champions' radiotherapeutic testing capability enhances their service portfolio, potentially attracting new pharmaceutical partnerships in a growing oncology segment.
Champions Oncology's new radioactive materials license represents a strategic expansion that strengthens their competitive positioning in the preclinical oncology services market. This regulatory approval creates a differentiated service offering by combining radiotherapeutic testing capabilities with their existing PDX platform.
From a business perspective, this capability enhancement diversifies Champions' service portfolio in the precisely targeted area of radiopharmaceuticals - a sector experiencing increased investment from biopharmaceutical companies. By offering integrated testing services, Champions potentially positions itself to capture research spending from pharmaceutical partners developing next-generation radiotherapeutics.
The "under one roof" approach creates operational efficiencies that could be attractive to drug developers looking to streamline their research processes. While the article provides no revenue projections or specific financial metrics related to this expansion, the move aligns with broader industry trends toward more specialized and integrated research services.
This capability enhancement represents a logical extension of Champions' existing business model that leverages their established PDX platform. The timing appears strategic as radiopharmaceuticals gain traction in oncology treatment approaches, potentially opening new partnership opportunities with companies operating in this specialized therapeutic area.
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.
Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft (PDX) models.
"This license marks a significant milestone in our capability to support biopharmaceutical partners in developing next-generation radiotherapeutics," stated Ronnie Morris, CEO of Champions Oncology. "By integrating this expertise with our well-characterized PDX platform, we are uniquely positioned to drive the advancement of radiopharmaceutical development with unparalleled translational precision."
This comprehensive program will support drug developers across a range of modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.
For partnership inquiries or to learn more, please contact us at https://www.championsoncology.com/contact-us.
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the significance of Champions Oncology's new radioactive materials license?
How will CSBR's new license impact their radiopharmaceutical development capabilities?
What types of therapeutic modalities will Champions Oncology (CSBR) support with their new license?
How does Champions Oncology's PDX platform complement their new radioactive materials license?
